Wednesday, February 1, 2017

Leukemia - Table of Contents alert Volume 31 Issue 2

If you are unable to see the message below, click here to view.

The Bass Center for Childhood Cancer & Blood Diseases at Stanford Children's Health is a leading center for the treatment of leukemia and lymphomas in children. Nationally ranked and part of NCI-designated Stanford Cancer Institute, we're committed to outstanding clinical care, groundbreaking research and state-of-the-art treatment for children with cancer. 

Learn more at 


Volume 31, Issue 2 (February 2017)

In this issue
Original Articles
Letters To The Editor

Also new
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Follow on Twitter
Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders.

Explore the benefits of submitting your next research article.



Acute myeloid leukemia therapy and the chosen people

E Estey and R P Gale

Leukemia 2017 31: 269-271; advance online publication, November 11, 2016; 10.1038/leu.2016.306

Full Text



Isocitrate dehydrogenase mutations in myeloid malignancies OPEN

B C Medeiros, A T Fathi, C D DiNardo, D A Pollyea, S M Chan and R Swords

Leukemia 2017 31: 272-281; advance online publication, October 10, 2016; 10.1038/leu.2016.275

Abstract | Full Text

Antigen receptor stereotypy in chronic lymphocytic leukemia

K Stamatopoulos, A Agathangelidis, R Rosenquist and P Ghia

Leukemia 2017 31: 282-291; advance online publication, November 4, 2016; 10.1038/leu.2016.322

Abstract | Full Text

Original Articles



Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia

L Quotti Tubi, S Canovas Nunes, A Brancalion, E Doriguzzi Breatta, S Manni, E Mandato, F Zaffino, P Macaccaro, M Carrino, K Gianesin, L Trentin, G Binotto, R Zambello, G Semenzato, C Gurrieri and F Piazza

Leukemia 2017 31: 292-300; advance online publication, August 1, 2016; 10.1038/leu.2016.209

Abstract | Full Text

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia

M Kontro, A Kumar, M M Majumder, S Eldfors, A Parsons, T Pemovska, J Saarela, B Yadav, D Malani, Y Fløisand, M Höglund, K Remes, B T Gjertsen, O Kallioniemi, K Wennerberg, C A Heckman and K Porkka

Leukemia 2017 31: 301-309; advance online publication, August 8, 2016; 10.1038/leu.2016.222

Abstract | Full Text

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia OPEN

A K Burnett, N H Russell, R K Hills, J Kell, O J Nielsen, M Dennis, P Cahalin, C Pocock, S Ali, S Burns, S Freeman, D Milligan and R E Clark on behalf of the UK NCRI AML Study Group

Leukemia 2017 31: 310-317; advance online publication, September 2, 2016; 10.1038/leu.2016.225

Abstract | Full Text

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

G Montalban-Bravo, X Huang, E Jabbour, G Borthakur, C D DiNardo, N Pemmaraju, J Cortes, S Verstovsek, T Kadia, N Daver, W Wierda, Y Alvarado, M Konopleva, F Ravandi, Z Estrov, N Jain, A Alfonso, M Brandt, T Sneed, H-C Chen, H Yang, C Bueso-Ramos, S Pierce, E Estey, Z Bohannan, H M Kantarjian and G Garcia-Manero

Leukemia 2017 31: 318-324; advance online publication, October 31, 2016; 10.1038/leu.2016.303

Abstract | Full Text


Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol

B O Wolthers, T L Frandsen, J Abrahamsson, B K Albertsen, L R Helt, M Heyman, Ó G Jónsson, L T Kõrgvee, B Lund, R A Raja, K K Rasmussen, M Taskinen, M Tulstrup, G E Vaitkevičienė, R Yadav, R Gupta and K Schmiegelow on behalf of the Nordic Society of Pediatric Hematology and Oncology (NOPHO)

Leukemia 2017 31: 325-332; advance online publication, July 25, 2016; 10.1038/leu.2016.203

Abstract | Full Text

Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy

C-H Pui, D Pei, S C Raimondi, E Coustan-Smith, S Jeha, C Cheng, W P Bowman, J T Sandlund, R C Ribeiro, J E Rubnitz, H Inaba, T A Gruber, W H Leung, J J Yang, J R Downing, W E Evans, M V Relling and D Campana

Leukemia 2017 31: 333-339; advance online publication, August 18, 2016; 10.1038/leu.2016.234

Abstract | Full Text


Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia

L M Saleh, W Wang, S E M Herman, N S Saba, V Anastas, E Barber, M Corrigan-Cummins, M Farooqui, C Sun, S M Sarasua, Z Zhao, N K Abousamra, O Elbaz, H A Abdelghaffar, A Wiestner and K R Calvo

Leukemia 2017 31: 340-349; advance online publication, June 24, 2016; 10.1038/leu.2016.181

Abstract | Full Text

Dynamics of microvesicle generation in B-cell chronic lymphocytic leukemia: implication in disease progression

J Boysen, M Nelson, G Magzoub, G P Maiti, S Sinha, M Goswami, S K Vesely, T D Shanafelt, N E Kay and A K Ghosh

Leukemia 2017 31: 350-360; advance online publication, August 2, 2016; 10.1038/leu.2016.217

Abstract | Full Text


Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma

F Linke, M Harenberg, M M Nietert, S Zaunig, F von Bonin, A Arlt, M Szczepanowski, H A Weich, S Lutz, C Dullin, P Janovská, M Krafčíková, L Trantírek, P Ovesná, W Klapper, T Beissbarth, F Alves, V Bryja, L Trümper, J Wilting and D Kube

Leukemia 2017 31: 361-372; advance online publication, August 18, 2016; 10.1038/leu.2016.232

Abstract | Full Text


Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma OPEN

G McNee, K L Eales, W Wei, D S Williams, A Barkhuizen, D B Bartlett, S Essex, S Anandram, A Filer, P A H Moss, G Pratt, S Basu, C C Davies and D A Tennant

Leukemia 2017 31: 373-381; advance online publication, July 11, 2016; 10.1038/leu.2016.187

Abstract | Full Text

Differentiation stage of myeloma plasma cells: biological and clinical significance

B Paiva, N Puig, M T Cedena, B G de Jong, Y Ruiz, I Rapado, J Martinez-Lopez, L Cordon, D Alignani, J A Delgado, M C van Zelm, J J M Van Dongen, M Pascual, X Agirre, F Prosper, J I Martín-Subero, M-B Vidriales, N C Gutierrez, M T Hernandez, A Oriol, M A Echeveste, Y Gonzalez, S K Johnson, J Epstein, B Barlogie, G J Morgan, A Orfao, J Blade, M V Mateos, J J Lahuerta and J F San-Miguel on behalf of GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study groups

Leukemia 2017 31: 382-392; advance online publication, August 1, 2016; 10.1038/leu.2016.211

Abstract | Full Text


A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis OPEN

S Verstovsek, M Talpaz, E Ritchie, M Wadleigh, O Odenike, C Jamieson, B Stein, T Uno and R A Mesa

Leukemia 2017 31: 393-402; advance online publication, August 1, 2016; 10.1038/leu.2016.215

Abstract | Full Text


A novel slug-containing negative-feedback loop regulates SCF/c-Kit-mediated hematopoietic stem cell self-renewal

Z Zhang, P Zhu, Y Zhou, Y Sheng, Y Hong, D Xiang, Z Qian, J Mosenson and W-S Wu

Leukemia 2017 31: 403-413; advance online publication, July 25, 2016; 10.1038/leu.2016.201

Abstract | Full Text

Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia

Y Fang, Y Yang, C Hua, S Xu, M Zhou, H Guo, N Wang, X Zhao, L Huang, F Yu, H Cheng, M L Wang, L Meng, T Cheng, W Yuan, D Ma and J Zhou

Leukemia 2017 31: 414-422; advance online publication, August 8, 2016; 10.1038/leu.2016.223

Abstract | Full Text

The immune receptor Trem1 cooperates with diminished DNA damage response to induce preleukemic stem cell expansion

W Du, S Amarachintha, A Wilson and Q Pang

Leukemia 2017 31: 423-433; advance online publication, August 29, 2016; 10.1038/leu.2016.242

Abstract | Full Text


HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation

W Herr, Y Eichinger, J Beshay, A Bloetz, S Vatter, C Mirbeth, E Distler, U F Hartwig and S Thomas

Leukemia 2017 31: 434-445; advance online publication, August 1, 2016; 10.1038/leu.2016.210

Abstract | Full Text


Activation of the complement cascade enhances motility of leukemic cells by downregulating expression of HO-1 OPEN

A Abdelbaset-Ismail, S Borkowska-Rzeszotek, E Kubis, K Bujko, K Brzeźniakiewicz-Janus, L Bolkun, J Kloczko, M Moniuszko, G W Basak, W Wiktor-Jedrzejczak and M Z Ratajczak

Leukemia 2017 31: 446-458; advance online publication, July 25, 2016; 10.1038/leu.2016.198

Abstract | Full Text


An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia

S P Koerner, M C André, J S Leibold, P C Kousis, A Kübler, M Pal, S P Haen, H-J Bühring, L Grosse-Hovest, G Jung and H R Salih

Leukemia 2017 31: 459-469; advance online publication, July 20, 2016; 10.1038/leu.2016.194

Abstract | Full Text

The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia

M Qorraj, H Bruns, M Böttcher, L Weigand, D Saul, A Mackensen, R Jitschin and D Mougiakakos

Leukemia 2017 31: 470-478; advance online publication, August 1, 2016; 10.1038/leu.2016.214

Abstract | Full Text


Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors OPEN

E Donato, O Croci, A Sabò, H Muller, M J Morelli, M Pelizzola and S Campaner

Leukemia 2017 31: 479-490; advance online publication, June 24, 2016; 10.1038/leu.2016.182

Abstract | Full Text

Letters To The Editor


Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome

M E Varney, K Choi, L Bolanos, S Christie, J Fang, L H Grimes, J P Maciejewski, J-I Inoue and D T Starczynowski

Leukemia 2017 31: 491-495; advance online publication, October 3, 2016; 10.1038/leu.2016.276

Full Text

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

M O Holmström, M D Hjortsø, S M Ahmad, Ö Met, E Martinenaite, C Riley, P Straten, I M Svane, H C Hasselbalch and M H Andersen

Leukemia 2017 31: 495-498; advance online publication, October 20, 2016; 10.1038/leu.2016.290

Full Text

NPM-ALK expression levels identify two distinct subtypes of paediatric anaplastic large cell lymphoma

E Pomari, G Basso, S Bresolin, M Pillon, E Carraro, E S d'Amore, G Viola, C Frasson, K Basso, P Bonvini and L Mussolin

Leukemia 2017 31: 498-501; advance online publication, October 24, 2016; 10.1038/leu.2016.292

Full Text

E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia

I-K Park, W Blum, S D Baker and M A Caligiuri

Leukemia 2017 31: 502-505; advance online publication, October 24, 2016; 10.1038/leu.2016.293

Full Text

Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms

V Visconte, B Przychodzen, Y Han, S T Nawrocki, S Thota, K R Kelly, B J Patel, C Hirsch, A S Advani, H E Carraway, M A Sekeres, J P Maciejewski and J S Carew

Leukemia 2017 31: 505-510; advance online publication, October 24, 2016; 10.1038/leu.2016.295

Full Text

Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial OPEN

M Larrayoz, M J J Rose-Zerilli, L Kadalayil, H Parker, S Blakemore, J Forster, Z Davis, A J Steele, A Collins, M Else, D Catovsky, D G Oscier and J C Strefford

Leukemia 2017 31: 510-514; advance online publication, October 26, 2016; 10.1038/leu.2016.298

Full Text

A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3? OPEN

E Troadec, S Dobbelstein, P Bertrand, N Faumont, F Trimoreau, M Touati, J Chauzeix, B Petit, D Bordessoule, J Feuillard, C Bastard and N Gachard

Leukemia 2017 31: 514-517; advance online publication, October 31, 2016; 10.1038/leu.2016.304

Full Text

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499

M R Smith, F Hong, H Li, L I Gordon, R D Gascoyne, E M Paietta, R H Advani, A Forero-Torres, S J Horning and B S Kahl

Leukemia 2017 31: 517-519; advance online publication, October 26, 2016; 10.1038/leu.2016.305

Full Text

Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation

G Berger, E van den Berg, B Sikkema-Raddatz, K M Abbott, R J Sinke, L B Bungener, A B Mulder and E Vellenga

Leukemia 2017 31: 520-522; advance online publication, October 31, 2016; 10.1038/leu.2016.310

Full Text

Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma

W Piao, D Chau, L M Yue, Y-L Kwong and E Tse

Leukemia 2017 31: 522-526; advance online publication, October 31, 2016; 10.1038/leu.2016.311

Full Text



Equivalence of BCSH and WHO diagnostic criteria for ET

C N Harrison, M F McMullin, A R Green and A J Mead

Leukemia 2017 31: 527-528; advance online publication, November 29, 2016; 10.1038/leu.2016.318

Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: